{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:25:46Z","timestamp":1778736346428,"version":"3.51.4"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Objectives: Although systemic chemotherapy (SC) is the mainstay for treating unresectable intrahepatic cholangiocarcinoma (ICC), its efficacy is limited and it causes severe systemic side effects. This study focuses on evaluating the effectiveness and safety of hepatic arterial infusion chemotherapy (HAIC) in combination with lenvatinib plus programmed death-1 (PD-1) inhibitors (HLP), compared to SC in combination with lenvatinib plus PD-1 inhibitors (SCLP) for unresectable ICC. Methods: We analyzed patients initially diagnosed with unresectable ICC at our center between March 2021 and December 2023, classifying them into HLP and SCLP groups according to treatment regimen. This study assessed and compared overall survival (OS), progression-free survival (PFS), tumor response, and safety outcomes across the two treatment groups. Results: This study enrolled 53 subjects in total; 25 were treated with HLP and 28 with SCLP. The two groups showed well-matched baseline characteristics. The HLP group reported an extended median OS (12.8 vs. 11.0 months, p = 0.310) and a prolonged median PFS (8.8 vs. 6.4 months, p = 0.043), compared to the SCLP group. The HLP group had a better objective response rate (ORR) (52% vs. 25%, p = 0.043) and disease control rate (DCR) (96% vs. 78.6%, p = 0.104). Based on OS (p = 0.019) and PFS (p = 0.032) results, those without extrahepatic metastasis seemed to benefit more significantly from the HLP regimen than from the SCLP regimen. The HLP group experienced fewer grade 3\u20134 adverse events (AEs) than the SCLP group. Conclusions: The HLP regimen for unresectable ICC is an effective and safe strategy and is potentially better suited for patients without extrahepatic metastases.<\/jats:p>","DOI":"10.3390\/curroncol32020087","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T05:55:22Z","timestamp":1738648522000},"page":"87","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study"],"prefix":"10.3390","volume":"32","author":[{"given":"Yingxiao","family":"Cai","sequence":"first","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Donghu District, Nanchang 330006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wu","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Donghu District, Nanchang 330006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangshuo","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Donghu District, Nanchang 330006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3497-1921","authenticated-orcid":false,"given":"Renhua","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The First Affiliated Hospital of Nanchang University, No. 17 Yongwaizheng Street, Donghu District, Nanchang 330006, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: Cholangiocarcinoma: Current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/cncr.29692","article-title":"Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma","volume":"122","author":"Esnaola","year":"2016","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jamcollsurg.2008.10.017","article-title":"Operations for intrahepatic cholangiocarcinoma: Single-institution experience of 158 patients","volume":"208","author":"Lang","year":"2009","journal-title":"J. Am. Coll. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1245\/s10434-008-0180-z","article-title":"A proposed staging system for intrahepatic cholangiocarcinoma","volume":"16","author":"Nathan","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","article-title":"Intrahepatic cholangiocarcinoma: Rising frequency, improved survival, and determinants of outcome after resection","volume":"248","author":"Endo","year":"2008","journal-title":"Ann. Surg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/cam4.299","article-title":"Cisplatin\/gemcitabine or oxaliplatin\/gemcitabine in the treatment of advanced biliary tract cancer: A systematic review","volume":"3","author":"Fiteni","year":"2014","journal-title":"Cancer Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000367746","article-title":"Current Status of Hepatic Arterial Infusion Chemotherapy","volume":"4","author":"Obi","year":"2015","journal-title":"Liver Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000342402","article-title":"Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy","volume":"1","author":"Kudo","year":"2012","journal-title":"Liver Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdp029","article-title":"Regional chemotherapy for unresectable primary liver cancer: Results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival","volume":"20","author":"Jarnagin","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/jso.23781","article-title":"Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma","volume":"111","author":"Boehm","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/ijc.33013","article-title":"Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies","volume":"147","author":"Oh","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaoncol.2020.0930","article-title":"A Phase 2 Multi-institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract Cancer","volume":"6","author":"Kim","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ueno, M., Ikeda, M., Sasaki, T., Nagashima, F., Mizuno, N., Shimizu, S., Ikezawa, H., Hayata, N., Nakajima, R., and Morizane, C. (2020). Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: Primary analysis results. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07365-4"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Shi, C., Li, Y., Yang, C., Qiao, L., Tang, L., Zheng, Y., Chen, X., Qian, Y., Yang, J., and Wu, D. (2022). Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.946861"},{"key":"ref_20","first-page":"4062","article-title":"Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors","volume":"110","author":"Guan","year":"2024","journal-title":"Int. J. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhang, W., Zhang, K., Liu, C., Gao, W., Si, T., Zou, Q., Guo, Z., Yang, X., Li, M., and Liu, D. (2023). Hepatic arterial infusion chemotherapy combined with anti-PD-1\/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: A real world study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1127349"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-21-0412","article-title":"Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection","volume":"27","author":"Jolissaint","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Yang, Z., Fu, Y., Wu, W., Hu, Z., Pan, Y., Wang, J., Chen, J., Hu, D., Zhou, Z., and Chen, M. (2023). Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1234342"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ishii, M., Itano, O., Morinaga, J., Shirakawa, H., and Itano, S. (2022). Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0266707"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1245\/s10434-023-14488-y","article-title":"Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma","volume":"31","author":"Franssen","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/hpb.12359","article-title":"Outcomes following resection of intrahepatic cholangiocarcinoma","volume":"17","author":"Tabrizian","year":"2015","journal-title":"HPB"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): Patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1200\/JCO.2021.39.15_suppl.4099","article-title":"Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial","volume":"39","author":"Jian","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Xie, L., Huang, J., Wang, L., Ren, W., Tian, H., Hu, A., Liang, J., Jiao, Y., Li, Y., and Zhou, Q. (2022). Lenvatinib Combined with a PD-1 Inhibitor as Effective Therapy for Advanced Intrahepatic Cholangiocarcinoma. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.894407"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1007\/s00262-023-03523-2","article-title":"Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: Effectiveness, safety, and biomarker analysis","volume":"72","author":"Chao","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Auer, T.A., Collettini, F., Segger, L., Pelzer, U., Mohr, R., Krenzien, F., Gebauer, B., Geisel, D., Hosse, C., and Schoning, W. (2023). Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma. Cancers, 15.","DOI":"10.3390\/cancers15092655"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Morawitz, J., Bruckmann, N.M., Jannusch, K., Kirchner, J., Antoch, G., Loosen, S., Luedde, T., Roderburg, C., and Minko, P. (2023). Update on Locoregional Therapies for Cholangiocellular Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15082368"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Owen, M., Makary, M.S., and Beal, E.W. (2023). Locoregional Therapy for Intrahepatic Cholangiocarcinoma. Cancers, 15.","DOI":"10.3390\/cancers15082384"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jso.23605","article-title":"Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: A population-based analysis","volume":"110","author":"Amini","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00270-011-0142-x","article-title":"Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: Factors associated with prolonged survival","volume":"35","author":"Hoffmann","year":"2012","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12032-016-0866-1","article-title":"The role of interventional radiology in the treatment of intrahepatic cholangiocarcinoma","volume":"34","author":"Ierardi","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1245\/s10434-022-11932-3","article-title":"Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin","volume":"29","author":"Martin","year":"2022","journal-title":"Ann. Surg. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29824","article-title":"Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone","volume":"122","author":"Konstantinidis","year":"2016","journal-title":"Cancer"},{"key":"ref_41","first-page":"3455","article-title":"Different interventional time of hepatic arterial infusion with PD-1 inhibitor for advanced biliary tract cancer: A multicenter retrospective study","volume":"12","author":"Zhang","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_42","first-page":"1026","article-title":"Local-regional therapy combined with toripalimab and lenvatinib in patients with advanced biliary tract cancer","volume":"13","author":"Wang","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"112872","DOI":"10.1016\/j.intimp.2024.112872","article-title":"Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma","volume":"140","author":"Ni","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1111\/cas.13806","article-title":"Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model","volume":"109","author":"Kimura","year":"2018","journal-title":"Cancer Sci."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Yang, J., Guo, Z., Song, M., Pan, Q., Zhao, J., Huang, Y., Han, Y., Ouyang, D., Yang, C., and Chen, H. (2023). Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFRbeta complex in hepatocellular carcinoma. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1212577"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/87\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:26:35Z","timestamp":1760027195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/2\/87"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["curroncol32020087"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32020087","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]}}}